Washington, D.C. Location

McNeely, Hare & War LLP
5335 Wisconsin Ave, NW, Suite 440,
Washington, DC 20015
(202) 274-0214

Directions | Email

Princeton, NJ Location

McNeely, Hare & War LLP
12 Roszel Road, Suite C104,
Princeton, NJ 08540
(609) 240-2533

Directions | Email

Translate Site:


Seminar Sign Up

FullSizeRender (1)

McNeely, Hare & War LLP
5335 Wisconsin Ave, NW
Suite 440
Washington, DC 20015
Phone: +01 202 253-4903
Fax: +01 202 478-1813
E-mail: rathinam@miplaw.com


Renita is a partner in the Washington, D.C. office of McNeely, Hare & War LLP, where her practice focuses on patent litigation.  She has served as litigation counsel in matters involving the chemical, pharmaceutical and mechanical arts, and has significant experience in all pre-trial, trial and post trial aspects of patent litigation, including appeals to the Federal Circuit, as well as pre-trial and parallel post grant proceedings before the U.S. Patent & Trademark Office.

Central to Renita’s practice is Hatch-Waxman Act analysis, and as such she has represented a number of pharmaceutical companies in ANDA/NDA related actions.  She also engages in pharmaceutical/biotechnology patent infringement and validity opinion practice and counseling particularly in connection with preparation of Paragraph IV Notifications under 505(j), as well as freedom-to-operate, due diligence and product clearance work, licensing and contract matters, including joint ventures.

Renita’s practice additionally includes analysis of the Biologics Price Competition and Innovation Act (BPCIA) and counseling with respect to litigation strategies particular to biosimilar, biobetter and interchangeable products and platform technologies.

Renita received her law degree from the University of North Carolina School of Law, and is a graduate of Georgetown University (M.S. Biochemistry and Molecular Biology) and Emory University (B.S. Biology).  Prior to joining McNeely Hare & War LLP, Renita was a partner with the law firm of Sughrue Mion, PLLC.  Renita is a member of the District of Columbia Bar and is admitted to practice before the United States Court of Appeals for the Federal Circuit, and the United States Patent & Trademark Office.


Representative Cases

Pfizer Inc. v. UCB Pharma GMBH v. Alkem Labs., Ltd. et al., 13-1110 (GMS) (D. Del. 2012)

Pentair Water Pool and Spa Inc. v. Hayward Industries, Inc., et al., 2:11-cv-10280-GW-MRW (C.D. CA 2011)

Merck Sharp & Dohme Corp. v. Accord Healthcare, Inc. USA, et al., 3:12-cv-3324-PGS-LHG (D. N.J. 2012)

AstraZeneca v. Hanmi Pharmaceutical, et al., 3:11-cv-00760 (D. N.J. 2013)  

International Stock Food Corp. v. Ridley, Inc. et al., 4:12-cv-00098-JAJ-RAW (S.D. IA 2012)

Sidel Participations SAS v. Blow Mold Services, Inc., 2:12-cv-00867-FMO-DTB (C.D. CA 2012)

CNH America v. Kinze Mfg., Civil Action No. 08-945 (D. Del. 2011)  

Metzger v. CNH America LLC, Civil Action No. 3:04-cv-50466 (N.D. Ill 2004)

Eli Lilly v. Wockhardt et al., Civil Action No. 1:08-cv-01547 (S.D. Ind. 2008)  

Titan Tire Corp. and The Goodyear Tire & Rubber Co. v. Case New Holland, et al., No. 07-63 (S.D. IA 2007)

Mars v. Natraceutical, S.A., Civil Action No. 02:07-cv-01574 (D.N.J. 2007)

Sanofi-aventis v. Wockhardt, C.A. No. 08-021 (D. Del. 2009)

Forest Labs. v. Wockhardt et al., Civil Action No. 08-021 (D. Del. 2008)  

Merck v. Ranbaxy, Civil Action No. 07-229 (D. Del. 2007)  

CNH America, LLC v. Clarke Machine, Civil Action No. 07-4183 (D. S.D. 2007)

In the Matter of Certain Buffer Systems and Components Thereof Used in Container Processing Lines, 337-TA-609 (2007)

Kinzenbaw v. Case Corp., Civil Action No. C01-133-LRR (N.D. IA 2001)

Speeches and Presentations

5th Biosimilars Summit – Innovations and Developments, “U.S. Biosimilars:  Legal Strategies in view of BPCIA and U.S. Post Grant Practice”, London, March 3-5, 2015

3rd International Conference and Exhibition on Biowaivers, Biologics and Biosimilars, topic: “Preparing for U.S. market entry – BPCIA and AIA – Strategy Considerations and Recent Developments,” Hyderabad, India, October 27-29, 2014

Preparing for U.S. Market Entry: Strategy Considerations in view of BPCIA and AIA, Biosimilars Global Congress 2014, London, September 17, 2014

‎6th Global Intellectual Property Convention‎, “US Post-Grant Proceedings in the Context of Collaboration, Licensing and Acquisition Agreements” Hyderabad, India‎, January 16-18, 2014

LES Annual Meeting, “U.S. Post-Grant Proceedings as Valuation and Negotiation Tools,” Toronto, October 2012

Key Provisions and Mechanics of AIA and PTO Rules, IIPRD, Mumbai, September 2012

Orange Book Listings: Requirements, Challenges & Considerations in Asserting Listed Patents, IIPRD Mumbai, September 2012

“Divided Infringement – Liability in Multi-Actor Scenarios Under Current U.S. Law,” Seoul, Korea (2011)

“U.S. Discovery Obligations and Process Overview,” Valencia, Spain; Montreal, Canada (2007); Mumbai, India (2009)

“Authorized Generics Practice and the Battle Over Exclusivity in the U.S. Market,” International Symposium, Global Perspective on Biotech and Pharma Patents, Ahmedabad, India (2007)

“Conducting Freedom to Operate Analyses,” Delhi, India (2006)

“Protection of Privileges and Immunities During Patent Litigation,” Delhi and Mumbai, India (2006)